Appendix G

Evidence Table per FDA Draft Guidance Document

Diabetic ulcers

Evidence Table - RCTs of diabetic ulcers (additional data on 20 selected studies)

Author Year Country	Population	# Patients (# ulcers)	Ulcer duration	Provider / Treatment duration / Method of wound size assessment	FDA Draft Guidance Document Recommendations						1° Outcome	2° Outcome
					Partial wound closure	Complete wound closure	3 months post-wound closure assessment	Wound size pre- & post-debridement	Antimicrobial treatment: Systemic versus topical	Antimicrobial treatment: Pre- versus during study		
Armstrong, 2000 USA	**Age (years)** 50 **% male** 83 **Setting** Hospital	97 (97)	ND	Patients /Up to 12 weeks/ Computerized planimetry	N	Y	ND	ND	ND	ND	Proportion of complete wound healing	Compliance
Baker, 1997 USA	**Age (years)** 53 **% male** 69 **Setting** Outpatients	80 (114)	6-640 days	Nursing staff / mean duration among 4 different arms 36-47 days/ Photographic imaging	N	Y[1]	ND	ND	ND	ND	Mean healing rate	
Caravaggi, 2000 Italy	**Age (years)** ND **% male** ND **Setting** Hospital	79 (79)	4 months	Not specified / Up to 11 weeks or until the ulcer was healed/ Not specified	N	Y	ND	ND	ND	ND	Percentage of healed ulcers and time to closure	Presence of fibrous slough and necrotic tissue, maceration, presence and amount of exudates, presence of odor and infection; pain intensity and frequency (VAS)

[1] Unclear whether complete or partial wound closure.
Abbreviations: Y = yes; N = no; ND = no data

Author Year Country	Population	# Patients (# ulcers)	Ulcer duration	Provider / Treatment duration / Method of wound size assessment	FDA Draft Guidance Document Recommendations						1° Outcome	2° Outcome
					Partial wound closure	Complete wound closure	3 months post-wound closure assessment	Wound size pre- & post-debridement	Antimicrobial treatment			
									Systemic versus topical	Pre- versus during study		
d'Hemecourt, 1998 USA	**Age (years)** 58.3 **% male** 74 **Setting** Outpatients	172 (172)	≥ 8 weeks	Not specified/ Up to 20 weeks/ Mechanical planimetry	N	Y	ND	ND	ND	ND	Percentage of patients achieving complete wound closure	Time to achieve complete wound closure; relative ulcer area from baseline to endpoint; wound evaluation score (included 6 parameters: erythema, edema, purulence, necrotic tissue, fibrin, and drainage)
Donaghue, 1998 USA	**Age (years)** 60 Range 30-81 **% male** 72 **Setting** ND	75 (75)	ND	Patients and caregivers /Up to 8 weeks or until ulcer was healed/ Not specified	Y	Y	ND	ND	ND	ND	Percentage of reduction of the ulcer area; rate of ulcer healing; time to healing	Patient's satisfaction
Kalani, 2003 Sweden	**Age (years)** 73 **% male** 71 **Setting** Outpatient by Foot care Team	85	>2 months	Foot care team /Up to 6 months/ Not specified	Y	Y	ND	ND	ND	ND	Number of patients healed, improved, unchanged, impaired, amputated	

[1] Unclear whether complete or partial wound closure.
Abbreviations: Y = yes; N = no; ND = no data

Author Year Country	Population	# Patients (# ulcers)	Ulcer duration	Provider / Treatment duration / Method of wound size assessment	FDA Draft Guidance Document Recommendations						1° Outcome	2° Outcome
					Partial wound closure	Complete wound closure	3 months post-wound closure assessment	Wound size pre- & post-debridement	Antimicrobial treatment: Systemic versus topical	Antimicrobial treatment: Pre- versus during study		
Lalau, 2002 France	**Age (years)** 62 **% male** 58 **Setting** Endocrinology, Rehabilitation, and Plastic Surgery Centers	77	Mean (months Tx: 4.9 C: 9.1	Nurses /Up to 6 weeks/ Mechanical planimetry	Y	Y	ND	ND	ND	ND	Healing success rate (proportion of patients with granulation tissue >75% of the wound area and proportion of patients having a 40% decrease in wound surface area)	Pain on dressing changes; the cumulative number of the dressing changes throughout the study period; the number of adverse events
Marston, 2003 USA	**Age (years)** 56 Range 27-83 **% male** 74 **Setting** Ambulatory	245	41-67 weeks	Not specified/ Up to 12 weeks or until complete wound closure/ Computerized planimatry	N	Y	ND	ND	ND	ND	Wound closure	Adverse events
Martinez de Jesus, 1997 Mexico	**Age (years)** 60 **% male** 42 **Setting** Hospital	140	Median (weeks) 8	Hospital staff /Up to 12 weeks/ Not specified	Y	Y	ND	ND	ND	ND	Mean reduction wound area	

[1] Unclear whether complete or partial wound closure.
Abbreviations: Y = yes; N = no; ND = no data

Author Year Country	Population	# Patients (# ulcers)	Ulcer duration	Provider / Treatment duration / Method of wound size assessment	FDA Draft Guidance Document Recommendations						1° Outcome	2° Outcome
					Partial wound closure	Complete wound closure	3 months post-wound closure assessment	Wound size pre- & post-debridement	Antimicrobial treatment: Systemic versus topical	Antimicrobial treatment: Pre- versus during study		
Mueller, 2003 USA	**Age (years)** 56 **% male** 77 **Setting** Hospital	64 (64)	ND	Not specified/ Up to 7 months/ Not specified	N	Y	Y	ND	ND	ND	Ulcer healing; time to healing Ulcer recurrence; time from initial ulcer healing to ulcer recurrence (average follow up after initial healing 2.1± 0.7 years)	Range of dorsiflexion; concentric peak torque of the plantar flexor muscles; peak plantar pressures on the forefoot during barefoot walking
Pai, 2001 India	**Age (years)** Median 58 **% male** 67 **Setting** Hospitalized	70 (70)	ND	Not specified/ Up to 6 weeks or until the ulcer was healed/ Not specified	Y	Y	ND	ND	ND	ND	Reduction in the surface area of the ulcer	
Pollack, 1997 USA	**Age (years)** 55 **% male** 72 **Setting** Ambulatory	281	>2 weeks	Not specified/ Up to 12 weeks/ Computerized planimetry	N	Y	Y	ND	ND	ND	Proportion of patients achieving wound closure; time to wound closure (closure in the 12 weeks was confirmed by additional follow up to 32 weeks)	

[1] Unclear whether complete or partial wound closure.
Abbreviations: Y = yes; N = no; ND = no data

Author Year Country	Population	# Patients (# ulcers)	Ulcer duration	Provider / Treatment duration / Method of wound size assessment	FDA Draft Guidance Document Recommendations						1° Outcome	2° Outcome
					Partial wound closure	Complete wound closure	3 months post-wound closure assessment	Wound size pre- & post-debridement	Antimicrobial treatment: Systemic versus topical	Antimicrobial treatment: Pre- versus during study		
Puttirutvong, 2004 Thailand	**Age (years)** 52.6 **% male** ND **Setting** ND	80	ND	Not specified/ Up to 6 months/ Not specified	Y	Y	Y	ND	ND	ND	Percentage of epithelization or healing; dates of complete healing	
Robson, 2002 USA	**Age (years)** 56 **% male** 80 **Setting** 15 centers, (ambulatory)	177	≥8 weeks	Patient or caregiver / 21 weeks/ Digital imaging	Y	Y	Y	ND	ND	ND	Proportion of patients with complete ulcer closure at or before week 21; percentage of ulcer area reduction at or before week 21	Proportion of patients with complete ulcer closure at each weekly visit; percentage of ulcer area reduction at each weekly visit; time to wound closure; 3-month follow up assessment of durability of wound closure
Saap, 2002 USA	**Age (years)** Range 18-80 **% male** ND **Setting** Ambulatory	143	≥ 2 weeks	Not specified/ 12 weeks (plus 3 more months follow up)/ Photographic imaging	N	Y	Y	Y	ND	ND	Debridement performance index; wound closure	

[1] Unclear whether complete or partial wound closure.
Abbreviations: Y = yes; N = no; ND = no data

Author Year Country	Population	# Patients (# ulcers)	Ulcer duration	Provider / Treatment duration / Method of wound size assessment	FDA Draft Guidance Document Recommendations						1° Outcome	2° Outcome
					Partial wound closure	Complete wound closure	3 months post-wound closure assessment	Wound size pre- & post-debridement	Antimicrobial treatment: Systemic versus topical	Antimicrobial treatment: Pre- versus during study		
Smiel, 1999 USA	**Age (years)** Range 23-93 **% male** 70 **Setting** Outpatient clinic	922	≥ 8 weeks	Not specified/ Up to 20 weeks or until complete wound healing was achieved/ Not specified	Y	Y	Y	ND	ND	ND	Functional assessment score	Adverse events; rate of ulcer recurrence and cosmesis of the scar (3 months after healing)
Tsang, 2003 Hong Kong	**Age (years)** 64 **% Male** 47.5 **Setting** Ambulatory	61 (61)	Mean (weeks) Tx1: 8.2 Tx2: 11.5 C: 12	Nurses /Up to 12 weeks/ Photographic imaging	N	Y	ND	ND	ND	ND	Time to complete healing	
Veves, 2002 USA	**Age (years)** 58.5 Range 23-85 **% male** 74 **Setting** Ambulatory	276	≥ 30 days	Patient and/or health care provider / Up to 12 weeks or until ulcer was healed/ Photographic imaging	N	Y	ND	ND	ND	ND	Healing rate	

[1] Unclear whether complete or partial wound closure.
Abbreviations: Y = yes; N = no; ND = no data

Author Year Country	Population	# Patients (# ulcers)	Ulcer duration	Provider / Treatment duration / Method of wound size assessment	FDA Draft Guidance Document Recommendations						1° Outcome	2° Outcome
					Partial wound closure	Complete wound closure	3 months post-wound closure assessment	Wound size pre- & post-debridement	Antimicrobial treatment			
									Systemic versus topical	Pre- versus during study		
Veves, 2001 USA	**Age (years)** 57 **% male** 78 **Setting** Ambulatory	208	11 months	Patient and investigators /Up to 12 weeks/ Computerized planimetry	N	Y	Y	ND	ND	ND	Complete wound closure	Improvement in undermining, maceration, exudates, granulation, eschar, and fibrin slough; safety evaluation up to 3 months after the 12 week follow up period
Wieman 1998 USA	**Age (years)** 58 **% male** 67 **Setting** Outpatient	382	≥ 8 weeks	Not specified/ Up to 20 weeks or until ulcer was completely healed/ Mechanical planimetry	Y	Y	Y	ND	ND	ND	Functional assessment score	Adverse events; recurrence (3 month evaluation after the 20 week follow up period)

[1] Unclear whether complete or partial wound closure.
Abbreviations: Y = yes; N = no; ND = no data